The Trustees of Columbia University in the City of New York,
Molecular Medicine, 630 West 168th Street, 8th Floor, Room
401, New York, NY 10032
art1@cumc.columbia.edu
Phone: 212-305-9418
Fax: 212-305-5052
Dr. Tall is an internationally recognized expert on plasma lipoproteins and atherosclerosis. He has recently elucidated links between hyperlipidemia, hematopoietic cell function and atherosclerosis.
His team will carry out studies on mechanisms of atherosclerosis in CH, including erythrophagocytosis and inflammasome activation. .
German Center for Cardiovascular Research (DZHK) Institute for Cardiovascular Prevention, LMU Munich Pettenkoferstr. 9, 80336 Munich, Germany,
oliver.Soehnlein@med.uni-muenchen.de
Phone: +49 89 4400 54677
Dr Soehnlein has pioneered studies showing the importance of neutrophils during atherogenesis and in atherosclerotic complications. He will focus on the role of neutrophils and NETosis in plaque development and complications in CH.
Spanish National Center for Cardiovascular Research CNIC, Madrid,
Calle Melchor Fernández Almagro 3,
28029 Madrid (Spain),
ahidalgo@cnic.es
Tel: 34 91 453 12 00 (Ext. 1504)
Dr Hidalgo has carried out groundbreaking studies on neutrophil biology, circadian variation, PLA formation and vascular inflammation including in atherosclerosis, myocardial infarction and stroke. He will assess the role of myeloid cells, platelets and their interaction in PLA in promoting atherosclerosis and thrombosis in CH.
The Broad Institute,
415 Main Street, Cambridge, MA 02142,
benjamin_ebert@dfci.harvard.edu
Tel: 617-525-4968
Fax: 617-525-4986
Dr Ebert has a longstanding interest in myeloid malignancies, and has pioneered studies of CH and CVD in humans. In addition, he has developed mouse models of CH and used them to study atherosclerosis and thrombosis. He will carry out studies on the relationship between CH mutations and atherosclerosis in mouse models and will probe the role of epigenetic factors.
Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)
Melchor Fernández Almagro, 3
28029 – Madrid (Spain)
jjfuster@cnic.es
Tel: (+34) 914531200 (Ext. 4304)
Dr Fuster’s research focuses on the interaction between the hematopoietic and the cardiovascular systems in the context of cardiovascular disease, particularly atherosclerosis and heart failure. He provided the first experimental evidence linking CH to atherosclerosis development in mouse models. He will carry out studies on the effects of several CH-related mutations on atherosclerosis.
Board of Trustees of the Leland Stanford Junior University,
Stanford University School of Medicine, Department of Pathology,
3373 Hillview Avenue, Room 218, Palo Alto, CA 94304,
sjaiswal@stanford.edu
Tel: 650-723-7211
Fax: 650-723-7409
Dr Jaiswal has a strong interest in the links between genomics and innate immunity. He first described the relationship between CH and atherosclerotic CVD in humans and mice. At Stanford he will use single cell analyses to understand how CH mutations affect cellular behavior within atherosclerotic plaques.
The Broad Institute, The Broad Institute,
415 Main Street, Cambridge, MA 02142,
sekar@broadinstitute.org
Phone: 617-643-3388.
Dr Kathiresan is a world’s leader in the genetic basis for myocardial infarction. He collaborated with Drs Ebert and Jaiswal in describing the relationship between CH and atherosclerotic CVD. He will investigate these relationships in a large human population and will determine how they are affected by genetic, environmental factors and treatment.
Munich Medizinische Klinik und Poliklinik I, Klinikum der Ludwig Maximilian Universität, München, Marchioninistraße 15, 81377 München,
steffen.massberg@med.uni-muenchen.de
Phone: +49 (0)89-4400-72371
Fax: +49 (0)89-4400-78870
Dr Massberg is a world leader in thrombopoiesis, thrombo-inflammation and mechanisms of thrombosis. A key expertise of the lab is intravital imaging in state-of-the art animal models of thrombosis and inflammatory conditions including atherosclerosis. He will study megakaryo- and thrombopoiesis, platelet functions interactions of platelets and immune cells, thrombosis and inflammation in CH.
Dr Natarajan studies the genetic basis of cardiovascular disease, including atherosclerosis. He collaborated with Drs Ebert and Jaiswal in describing the relationship between CH and atherosclerotic CVD. He will investigate these relationships in a large human population and will determine how they are affected by genetic, environmental factors and treatment.
The Trustees of Columbia University in the City of New York, Molecular Medicine
630 West 168th Street, 8th Floor, Room 401, New York, NY 10032
iat1@columbia.edu
Phone: 212-305-9430
Fax: 212-305-4834
Dr. Tabas is a renowned expert in the cellular biology of atherosclerosis. He is particularly interested in the roles of inflammation resolution and defective efferocytosis in atherosclerosis which he has found to be defective in the context of CH. His expertise in advanced plaque assessment, including apoptosis, in-situ efferocytosis, resolution assays, evaluation of phagocytic mediators in lesions, will be shared throughout the network.
The Trustees of Columbia University in the City of New York,
Molecular Medicine, 630 West 168th Street, 8th Floor, Room
401, New York, NY 10032
lao2106@cumc.columbia.edu
Phone: 212-305-9418
Fax: 212-305-5052
